<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02549976</url>
  </required_header>
  <id_info>
    <org_study_id>2015-4</org_study_id>
    <nct_id>NCT02549976</nct_id>
  </id_info>
  <brief_title>Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis</brief_title>
  <acronym>DESTIN</acronym>
  <official_title>Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate digestive damage in CD 5 to 10 years after diagnosis in
      the GETAID centers included in the RAPID study. Secondary objective is to identify predictive
      factors of the evolution digestive damage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Crohn's disease (CD) is a chronic inflammatory disorder of the bowel that is
      characterized by periods of clinical remission alternating with periods of recurrence.
      Persistent inflammation is believed to lead to progressive bowel damage that, over time, will
      manifest in the development of strictures, fistulae, and abscesses. The recent development of
      the Lemann index allows us to precisely assess digestive damage in CD. The aim of the present
      study is to evaluate digestive damage and associated predictive factors in CD 5 to 10 years
      after diagnosis.

      Methods: Prospective, multicenter, international, transversal, observational study. Patients
      who completed the RAPID trial (evaluating the benefits on the course of CD of an early
      prescription of azathioprine compared with conventional step-care therapy) will be eligible.
      Digestive damage will be assessed using methods described in the Lemann index protocol,
      dependent on CD location (abdominal MRI obligatory). The total duration of study
      participation for 1patient will be â‰¤4 months.

      Aims: The primary objective is to evaluate digestive damage in CD 5 to 10 years after
      diagnosis in the GETAID centers included in the RAPID study. Secondary objective is to
      identify predictive factors of the evolution digestive damage.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Digestive damage</measure>
    <time_frame>5 to 10 years after diagnosis</time_frame>
    <description>Evaluate digestive damage in Crohn's Disease by using Lemann Index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of the digestive damage evolution</measure>
    <time_frame>5 to 10 years after diagnosis</time_frame>
    <description>Evaluate digestive damage per organ (upper intestinal tract, small bowel, colon or rectum, anal or perianal) by using Lemann Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of the digestive damage evolution</measure>
    <time_frame>5 to 10 years after diagnosis</time_frame>
    <description>Determine correlation between Lemann Index and factors measured at diagnosis and then 5 to 10 years after diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of Lemann Index</measure>
    <time_frame>5 to 10 years after diagnosis</time_frame>
    <description>Variation of Lemann Index 5 to 10 years after diagnosis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Evaluation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digestive damage will be assessed on patients by using the methods described in the Lemann index protocol, dependant of Crohn's disease locations.
All patients will have clinical examination and abdominal magnetic resonance imaging analyses. Upper endoscopy, colonoscopy, and pelvic magnetic resonance imaging analyses will be performed according to disease locations :
Upper tract location : upper endoscopy
Colorectal location : colonoscopy
Perianal location : pelvic MRI
All patients : abdominal MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Abdominal MRI</intervention_name>
    <description>Abdominal MRI to realize within 4 months following inclusion</description>
    <arm_group_label>Evaluation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Upper endoscopy</intervention_name>
    <description>Upper endoscopy to realize within 4 months following inclusion</description>
    <arm_group_label>Evaluation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colonoscopy</intervention_name>
    <description>Colonoscopy to realize within 4 months following inclusion</description>
    <arm_group_label>Evaluation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pelvic MRI</intervention_name>
    <description>Pelvic MRI to realize within 4 months following inclusion</description>
    <arm_group_label>Evaluation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients over 18 years old

          -  Active or Inactive Crohn's Disease

          -  Previously enrolled in RAPID clinical trial

        Exclusion Criteria:

          -  Pregnant or nursing woman

          -  Patient with a contraindication or who decline to have study exams (MRI and endoscopy)

          -  Other medical or psychiatric or serious chronic conditions or according to the
             physician's discretion that could affect the patient's cooperation or the capacity to
             follow study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Pariente, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Cosnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU NICE</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMM</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Pessac</name>
      <address>
        <city>Pessac</city>
        <zip>33700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.getaid.org</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D'Haens G, Loftus EV Jr, Louis E, PanÃ©s J, SchÃ¶lmerich J, Schreiber S, Vecchi M, Branche J, Bruining D, Fiorino G, Herzog M, Kamm MA, Klein A, Lewin M, Meunier P, Ordas I, Strauch U, Tontini GE, Zagdanski AM, Bonifacio C, Rimola J, Nachury M, Leroy C, Sandborn W, Colombel JF, Cosnes J. Development of the LÃ©mann index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology. 2015 Jan;148(1):52-63.e3. doi: 10.1053/j.gastro.2014.09.015. Epub 2014 Sep 21.</citation>
    <PMID>25241327</PMID>
  </reference>
  <reference>
    <citation>Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF; Groupe d'Etude ThÃ©rapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology. 2013 Oct;145(4):758-65.e2; quiz e14-5. doi: 10.1053/j.gastro.2013.04.048. Epub 2013 Apr 30.</citation>
    <PMID>23644079</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>Digestive Damage</keyword>
  <keyword>Lemann Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

